- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05418868
A Study to Investigate Pharmacokinetics, Safety and Tolerability of Long-Acting Cabotegravir Plus Recombinant Human Hyaluronidase PH20 in Healthy Adult Participants
January 5, 2024 updated by: ViiV Healthcare
A Phase I, Multi-centre, Open-label, Single Dose Escalation Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Long-acting Cabotegravir Co-administered With Recombinant Human Hyaluronidase PH20 (rHuPH20) in Healthy Adult Volunteers
This is an open-label, dose-escalation study to investigate the safety, tolerability, and pharmacokinetics (PK) of single subcutaneous (SC) administration of long acting (LA) Cabotegravir (CAB) 200 milligrams per milliliter (mg/mL) with Recombinant Human Hyaluronidase PH20 (rHuPH20) (Part A) and CAB 400 mg/mL without rHuPH20 (Part C) and CAB 400 mg/mL with rHuPH20 (Part D).
Part A of the study (CAB 200 mg/mL with rHuPh20) has been closed to further enrolment based on preliminary results.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
60
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: US GSK Clinical Trials Call Center
- Phone Number: 877-379-3718
- Email: GSKClinicalSupportHD@gsk.com
Study Contact Backup
- Name: EU GSK Clinical Trials Call Center
- Phone Number: +44 (0) 20 89904466
- Email: GSKClinicalSupportHD@gsk.com
Study Locations
-
-
Florida
-
Orlando, Florida, United States, 32806
- Recruiting
- GSK Investigational Site
-
Contact:
- US GSK Clinical Trials Call Center
- Phone Number: 877-379-3718
- Email: GSKClinicalSupportHD@gsk.com
-
Contact:
- EU GSK Clinical Trials Call Centre
- Phone Number: +44 (0) 20 8990 4466
- Email: GSKClinicalSupportHD@gsk.com
-
Principal Investigator:
- James Dale Taylor II
-
-
Nevada
-
Las Vegas, Nevada, United States, 89113
- Recruiting
- GSK Investigational Site
-
Contact:
- US GSK Clinical Trials Call Center
- Phone Number: 877-379-3718
- Email: GSKClinicalSupportHD@gsk.com
-
Contact:
- EU GSK Clinical Trials Call Centre
- Phone Number: +44 (0) 20 8990 4466
- Email: GSKClinicalSupportHD@gsk.com
-
Principal Investigator:
- Darin Brimhall
-
-
New Jersey
-
Berlin, New Jersey, United States, 08009
- Recruiting
- GSK Investigational Site
-
Principal Investigator:
- Michael A Hassman
-
Contact:
- US GSK Clinical Trials Call Center
- Phone Number: 877-379-3718
- Email: GSKClinicalSupportHD@gsk.com
-
Contact:
- EU GSK Clinical Trials Call Centre
- Phone Number: +44 (0) 20 8990 4466
- Email: GSKClinicalSupportHD@gsk.com
-
-
Texas
-
Austin, Texas, United States, 78744
- Recruiting
- GSK Investigational Site
-
Principal Investigator:
- Craig Boyle
-
Contact:
- US GSK Clinical Trials Call Center
- Phone Number: 877-379-3718
- Email: GSKClinicalSupportHD@gsk.com
-
Contact:
- EU GSK Clinical Trials Call Centre
- Phone Number: +44 (0) 20 8990 4466
- Email: GSKClinicalSupportHD@gsk.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 55 years (Adult)
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- At the time of obtaining informed consent, participants age should be equal to or greater than (=>)18 years and equal to or less than (=<) 55 years.
- Participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, and cardiac monitoring.
- Body weight =>40 kilogram (kg) and body mass index (BMI) within the range =>18 to =<32 kilogram per meter square (kg/m^2).
- Participants who are negative on a single test for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (approved molecular polymerase chain reaction [PCR] laboratory or point of care test), performed on the day of admission. A negative result is required prior to the administration of study intervention on Day 1.
- Contraceptive use by men and women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
- Capable of giving written informed consent.
Exclusion Criteria:
- Current presence or history of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, or neurological disorders.
- Current or chronic history of liver disease or known hepatic or biliary abnormalities.
- History of ongoing or clinically relevant seizure disorder within the previous 2 years, including participants who have required treatment for seizures within this time period.
- Positive SARS-CoV-2 polymerase chain reaction test, having signs and symptoms which in the opinion of the investigator are suggestive of coronavirus disease 2019 (COVID-19) (i.e., fever, cough etc) within 14 days of inpatient admission, or having contact with known COVID-19 positive person/s in the 14 days prior to inpatient admission.
- Human immunodeficiency virus (HIV-1 or HIV-2) infection as indicated by positive antibody/antigen test.
- History of or on-going high-risk behaviors that, in the opinion of the investigator, may put the participant at increased risk for HIV infection including, but not limited to, participants in HIV discordant relationships, or men who report current or prior unprotected anal sex with other men and those reporting prior or current injecting drug use.
- Presence of hepatitis B surface antigen (HBsAg), or positive hepatitis C antibody test result at screening or within 3 months prior to first dose of study treatment.
- Abnormal blood pressure.
- Evidence of previous myocardial infarction.
- Any conduction abnormality (including but not specific to left or right complete bundle branch block, atrioventricular [AV] block [2nd degree or higher], Wolff- Parkinson-White [WPW] syndrome).
- Any significant arrhythmia which, in the opinion of the investigator or the medical monitor, will interfere with the safety for the individual participant.
- One or more exclusionary values for a screening Electrocardiogram (ECG).
- Alanine transaminase (ALT) >1.5x upper limit of normal (ULN).
- Bilirubin >1.5xULN (isolated bilirubin >1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin <35 percent [%]).
- Estimated Glomerular Filtration Rate (eGFR) <60 milliliter per minute (mL/min) using the Chronic Kidney Disease
- Improved Prediction Equations (CKD-EPI) Creatinine Equation (2021).
- Hemoglobin <12.5 gram per deciliter (g/dL) for men and <11 g/dL for women.
- Positive pre-study drug/alcohol screen.
- Regular use of tobacco- or nicotine-containing products within 3 months prior to screening; or urinary cotinine levels indicative of smoking or history or regular use of tobacco- or nicotine-containing products (e.g., nicotine patches or vaporizing devices).
- Regular alcohol consumption within 6 months prior to the study defined as an average weekly intake of >14 units for males or >7 units for females.
- Regular use of known drugs of abuse.
- Concurrent participation in another clinical trial (except imaging trials); or has participated in a clinical trial and received an investigational product within the following time period prior to the first dosing day in this study: 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer).
- Participation in the study would result in loss of blood or blood products in excess of 500 mL within 56 days.
- Exposure to more than four (4) new chemical entities within 12 months prior to the first dosing day.
- History of sensitivity to any of the study interventions (or components thereof), a history of drug allergy or other allergy that, in the opinion of the investigator or medical monitor, contraindicates their participation, including a known hypersensitivity to hyaluronidases.
- Current or anticipated need for chronic anti-coagulation therapy.
- Hereditary coagulation and platelet disorders (e.g., hemophilia or Von Willebrand disease [VWD]).
- Participant has a tattoo overlying the location of injection or an underlying skin disease or condition (e.g., infection, inflammation, dermatitis, eczema, drug rash, drug allergy, psoriasis, food allergy, urticaria) that, in the opinion of the investigator, may interfere with interpretation of injection site reactions or administration of study intervention.
- Any other clinical condition, behavior or prior therapy that, in the opinion of the investigator, would make the participant unsuitable for the study; unable to comply with dosing requirements; or unable to comply with study visits.
- Participant who in the investigator's judgment poses a significant suicidality risk. Participant's history of suicidal behavior and/or suicidal ideation should be considered when evaluating for suicide risk.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Part C: Participants receiving CAB 400 mg/mL
|
CAB 400 mg/mL will be administered.
|
Experimental: Part D: Participants receiving CAB 400 mg/mL with rHuPH20
|
rHuPH20 will be administered.
CAB 400 mg/mL will be administered.
|
Experimental: Part A: Participants receiving CAB 200 mg/mL with rHuPH20
Part A of the study (CAB 200 mg/mL with rHuPh20) has been closed to further enrolment based on preliminary results.
|
CAB 200 mg/mL will be administered.
rHuPH20 will be administered.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Maximum observed plasma concentration (Cmax) of Cabotegravir
Time Frame: Up to Week 52
|
Up to Week 52
|
|
Time of maximum observed plasma concentration (tmax) of Cabotegravir
Time Frame: Up to Week 52
|
Up to Week 52
|
|
Area under the concentration - time curve from time zero to infinity (AUC[0-inf]) of Cabotegravir
Time Frame: Up to Week 52
|
Up to Week 52
|
|
Area under the concentration - time curve from time zero to time of last quantifiable concentration or 4 weeks following the injection whichever is earlier (AUC[0-t]) of Cabotegravir
Time Frame: Up to Week 52
|
Up to Week 52
|
|
Plasma Concentration of Cabotegravir at Week 4
Time Frame: Week 4
|
Week 4
|
|
Plasma Concentration of Cabotegravir at Week 8
Time Frame: Week 8
|
Week 8
|
|
Plasma Concentration of Cabotegravir at Week 12
Time Frame: Week 12
|
Week 12
|
|
Plasma Concentration of Cabotegravir at Week 24
Time Frame: Week 24
|
Week 24
|
|
Apparent terminal phase half-life (t1/2) of Cabotegravir
Time Frame: Up to Week 52
|
Up to Week 52
|
|
Apparent long-acting absorption rate constant (KA-LA) of Cabotegravir
Time Frame: Up to Week 52
|
Up to Week 52
|
|
Number of Participants with Non-serious Adverse Events (non-SAEs) and Serious Adverse Events (SAEs)
Time Frame: Up to Week 52
|
Up to Week 52
|
|
Number of Participants with AEs by Severity
Time Frame: Up to Week 52
|
Up to Week 52
|
|
Absolute value of Hematology parameter: Platelet count (cells per microliter)
Time Frame: Up to Week 52
|
Up to Week 52
|
|
Absolute values of Hematology parameters: Reticulocytes (Percentage of reticulocytes)
Time Frame: Up to Week 52
|
Up to Week 52
|
|
Absolute values of Hematology parameters: Hematocrit (Proportion of red blood cells in blood)
Time Frame: Up to Week 52
|
Up to Week 52
|
|
Absolute values of Hematology parameters: Hemoglobin (Hgb) (grams per deciliter)
Time Frame: Up to Week 52
|
Up to Week 52
|
|
Absolute value of Hematology parameter: Red Blood Cell Count (RBC) (million cells per microliter)
Time Frame: Up to Week 52
|
Up to Week 52
|
|
Absolute value of Hematology parameter: Mean Corpuscle Volume (MCV) (Femtoliters)
Time Frame: Up to Week 52
|
Up to Week 52
|
|
Absolute value of Hematology parameter: Mean Corpuscle Hemoglobin (MCH) (Picograms)
Time Frame: Up to Week 52
|
Up to Week 52
|
|
Absolute values of Hematology parameters: Differential count of Neutrophils, Lymphocytes, Monocytes, Eosinophils, Basophils (giga cells per liter)
Time Frame: Up to Week 52
|
Up to Week 52
|
|
Absolute values of Clinical Chemistry parameters: Glucose (fasting), Blood Urea Nitrogen (BUN), Creatinine, Sodium, Potassium, Calcium, Direct Bilirubin and Total Bilirubin (milligrams per deciliter)
Time Frame: Up to Week 52
|
Up to Week 52
|
|
Absolute values of Clinical Chemistry parameters: AST/SGOT, ALT/ SGPT, ALP and CPK (International Units per liter)
Time Frame: Up to Week 52
|
Clinical chemistry parameters such as Aspartate Aminotransferase (AST) / Serum Glutamic-Oxaloacetic Transaminase (SGOT), Alanine Aminotransferase (ALT)/ Serum Glutamic-Pyruvic Transaminase and (SGPT), Alkaline phosphatase (ALP) and Creatinine Phosphokinase (CPK) will be analyzed.
|
Up to Week 52
|
Absolute values of Clinical chemistry parameters: Albumin and Total Protein (Grams per deciliter)
Time Frame: Up to Week 52
|
Up to Week 52
|
|
Change from Baseline in Hematology parameter: Platelet count (cells per microliter)
Time Frame: Baseline (Day 1) and up to Week 52
|
Baseline (Day 1) and up to Week 52
|
|
Change from Baseline in Hematology parameters: Reticulocytes (Percentage of reticulocytes)
Time Frame: Baseline (Day 1) and up to Week 52
|
Baseline (Day 1) and up to Week 52
|
|
Change from Baseline in Hematology parameters: Hematocrit (Proportion of red blood cells in blood)
Time Frame: Baseline (Day 1) and up to Week 52
|
Baseline (Day 1) and up to Week 52
|
|
Change from Baseline in Hematology parameters: Hgb (grams per deciliter)
Time Frame: Baseline (Day 1) and up to Week 52
|
Baseline (Day 1) and up to Week 52
|
|
Change from Baseline in Hematology parameter: RBC Count (million cells per microliter)
Time Frame: Baseline (Day 1) and up to Week 52
|
Baseline (Day 1) and up to Week 52
|
|
Change from Baseline in Hematology parameter: MCV (Femtoliters)
Time Frame: Baseline (Day 1) and up to Week 52
|
Baseline (Day 1) and up to Week 52
|
|
Change from Baseline in Hematology parameter: MCH (picograms)
Time Frame: Baseline (Day 1) and up to Week 52
|
Baseline (Day 1) and up to Week 52
|
|
Change from Baseline in Hematology parameters: Differential count of Neutrophils, Lymphocytes, Monocytes, Eosinophils, Basophils (Giga cells per liter)
Time Frame: Baseline (Day 1) and up to Week 52
|
Baseline (Day 1) and up to Week 52
|
|
Change from Baseline in Clinical Chemistry parameters: Glucose (fasting), BUN, Creatinine, Sodium, Potassium, Calcium, Direct Bilirubin and Total Bilirubin (milligrams per deciliter)
Time Frame: Baseline (Day 1) and up to Week 52
|
Baseline (Day 1) and up to Week 52
|
|
Change from Baseline in Clinical Chemistry parameters: AST/SGOT, ALT/ SGPT, ALP and CPK (International Units per liter)
Time Frame: Baseline (Day 1) and up to Week 52
|
Baseline (Day 1) and up to Week 52
|
|
Change from Baseline in Clinical chemistry parameters: Albumin and Total Protein (Grams per deciliter)
Time Frame: Baseline (Day 1) and up to Week 52
|
Baseline (Day 1) and up to Week 52
|
|
Number of participants with maximum toxicity grades increase from Baseline in hematology and clinical chemistry
Time Frame: Up to Week 52
|
Up to Week 52
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Dose proportionality of Cabotegravir based on AUC(0-inf)
Time Frame: Up to Week 52
|
Up to Week 52
|
|
Dose proportionality of Cabotegravir based on AUC(0-t)
Time Frame: Up to Week 52
|
Up to Week 52
|
|
Dose proportionality of Cabotegravir based on Cmax
Time Frame: Up to Week 52
|
Up to Week 52
|
|
Dose proportionality of Cabotegravir based on plasma concentration
Time Frame: Weeks 4, 8, 12 and 24
|
Weeks 4, 8, 12 and 24
|
|
Number of participants with maximum post-baseline QTc values compared to baseline by category (to <=450 milliseconds (msec) or no change, to >450 msec to <=480 msec, to >480 msec to <=500 msec, and to >500 msec)
Time Frame: Up to Week 52
|
Up to Week 52
|
|
Number of participants with maximum post-baseline increase in QTc values compared to baseline based on category (increase <=30 msec, increase of 31-60 msec, and increase of >60 msec)
Time Frame: Up to Week 52
|
Up to Week 52
|
|
Number of participants with worst case post-baseline values relative to potential clinical importance criteria compared to baseline for diastolic blood pressure (DBP), systolic blood pressure (SBP) and pulse rate
Time Frame: Up to Week 52
|
Number of participants with worst case post-baseline values relative to potential clinical importance criteria compared to baseline will be categorized into change to low, change to within range or no change, and change to high.
|
Up to Week 52
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: GSK Clinical Trials, ViiV Healthcare
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
June 14, 2022
Primary Completion (Estimated)
November 11, 2025
Study Completion (Estimated)
November 12, 2025
Study Registration Dates
First Submitted
June 9, 2022
First Submitted That Met QC Criteria
June 9, 2022
First Posted (Actual)
June 14, 2022
Study Record Updates
Last Update Posted (Estimated)
January 8, 2024
Last Update Submitted That Met QC Criteria
January 5, 2024
Last Verified
January 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
- RNA Virus Infections
- Virus Diseases
- Infections
- Blood-Borne Infections
- Communicable Diseases
- Sexually Transmitted Diseases, Viral
- Sexually Transmitted Diseases
- Lentivirus Infections
- Retroviridae Infections
- Immunologic Deficiency Syndromes
- Immune System Diseases
- Urogenital Diseases
- Genital Diseases
- HIV Infections
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Enzyme Inhibitors
- Anti-HIV Agents
- Anti-Retroviral Agents
- HIV Integrase Inhibitors
- Integrase Inhibitors
- Cabotegravir
Other Study ID Numbers
- 218012
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
Qualified researchers may request access to anonymized individual patient-level data (IPD) and related study documents of the eligible studies via the Data Sharing Portal.
Details on GSK's data sharing criteria can be found at: https://www.gsk.com/en-gb/innovation/trials/data-transparency/
IPD Sharing Time Frame
Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.
IPD Sharing Access Criteria
Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place.
Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV Infections
-
University of MinnesotaWithdrawnHIV Infections | HIV/AIDS | Hiv | AIDS | Aids/Hiv Problem | AIDS and InfectionsUnited States
-
University of California, San DiegoUniversity of California, Los Angeles; University of Southern California; California... and other collaboratorsCompleted
-
Gérond'ifRecruiting
-
University of California, DavisCompleted
-
University of California, San DiegoNational Center for Complementary and Integrative Health (NCCIH)CompletedHIV PositiveUnited States
-
University of ChicagoUniversity of Athens; National Development and Research Institutes, Inc.Completed
-
HIV Prevention Trials NetworkNational Institute on Drug Abuse (NIDA); National Institute of Allergy and...CompletedHIV PositiveIndonesia, Ukraine, Vietnam
-
University of ZimbabweCompleted
-
Florida International UniversityCompleted
-
Boston Children's HospitalNational Institute on Minority Health and Health Disparities (NIMHD)Completed
Clinical Trials on Cabotegravir 200 mg/mL
-
ViiV HealthcareCompletedHIV Infections | Infection, Human Immunodeficiency VirusUnited States
-
Shaheed Zulfiqar Ali Bhutto Medical UniversityCompletedCytokine Release Syndrome | Covid-19 PneumoniaPakistan
-
Kadmon Corporation, LLCQuotient SciencesCompletedHealthy VolunteersUnited Kingdom
-
ViiV HealthcareCompletedHIV InfectionsUnited States, New Zealand
-
Teva Branded Pharmaceutical Products R&D, Inc.FHI 360Completed
-
Seoul National University HospitalSMG-SNU Boramae Medical CenterCompleted
-
ViiV HealthcareCompletedInfection, Human Immunodeficiency VirusUnited States
-
University of Michigan Rogel Cancer CenterWithdrawnProstate CancerUnited States
-
Enrollme.ru, LLCDanone NutriciaCompleted
-
Maimónides Biomedical Research Institute of CórdobaConsejería de Salud y Familias - Junta de Andalucía; Red Andaluza de Ensayos...Completed